Evaluation Of Risk Factors In Cardiovascular Patients With Diagnosis Of Systemic Lupus Erythematosus (SLE)

  • Edienny Augusta Tocantins Viana Lobato
  • Fernanda Araújo Santos
  • Ana Rachel Koury Marinho
  • Alvaro Alves Dos Santos Neto
  • Suzana Maria Klautau Ferreira
  • Renan dos Santos Cortinhas
  • Giordana Pereira De Sousa UNIVERSIDADE DO ESTADO DO PARÁ
  • Francisco De Almeida Teixeira Neto
  • Vivianne De Paula Reis Guimarães
  • Igor Batista Nascimento
  • Caio Nogueira Oliveira
  • Priscila Nathyelly Dos Santos Graim
  • Anderson Phelipe Dias Sabry Azar

Abstract

Title: Evaluation of risk factors in cardiovascular patients with diagnosis of Systemic Lupus Erythematosus (SLE).


Background: prevalence of cardiovascular risk factors in lupic patients.This study aimed to evaluate the presence of cardiovascular risk factors in patients diagnosed with SLE in a Rheumatology Ambulatory, comparing groups with and without SLE nephritis.


Methods: a quantitative, observational and cross-sectional study was carried out during the period from November 2016 to June 2017. 86 patients were interviewed using specific protocol.


Conclusions: among the cardiovascular risk factors evaluated, systemic hypertension was more frequent in SLE patients (33.7%), followed by smoking (17.4%) and diabetes mellitus (5.8%). There was, however, no difference between the frequency of these comorbidities in the groups with and without lupus nephritis.

References

1 - Cunha BM et al. Frequência de síndrome metabólica em pacientes com nefrite lúpica. Rev. Bras Reumatol 2008 Oct; 48(5): 267-73.
2 – Sinicato NA, Cardoso PAS, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev. 2013 Feb;9(1):15-9.
3 – Couser WG. Patogênese e tratamento da glomerulonefrite - uma atualização. J Bras Nefrol 2016;38(1):107-122.
4 - lori TO, Enofe N, Oommen A, Cobb J, Navarrete J, et al.. Comparison of Outcomes between Individuals with Pure and Mixed Lupus Nephritis: A Retrospective Study. Research Article, Published online: jun, 2016.
5 - Urowitz MB, Ibañez D, Su J, Gladman DD. Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. J Rheumatol. 2016 May;43(5):875-9.
6 - Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012 Aug;27(8):3248-54.
7 - Shaharir SS, Mustafar R, Mohd R, Mohd Said MS, Gafor HA. Persistent hypertension in lupus nephritis and the associated risk factors. Clin Rheumatol. 2015 Jan;34(1):93-7.
8 - Atukorala I, Weeratunga P, Kalubowila J, et al. Cardiovascular risk in lupus nephritis: Do renal disease-related and other traditional risk factors play a role? Saudi J Kidney Dis Transpl 2015;26(3):526-535.
9 - Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erithematosus: just another comorbidity? Semin Arthritis Rheum. 2016 Apr;45(5):604-10.
10 - Farschou M. et al. High Risk of Ischemic Heart Disease in Patients with Lupus Nephritis. The Journal of Rheumatology Nov2011, 38 (11) 2400-5.
11 - Petri M. et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86.
12 - Balsamo S, Nascimento DC, Tibana RA, Santana FS, Mota LMH, Santos-Neto LL. The quality of life of patients with lupus erythematosus influences cardiovascular capacity in 6-minute walk test. Rev. Bras. Reumatol. 2013. Feb; 53( 1 ): 81-87.
13 - Medeiros MM, Xavier de Oliveira IM, Ribeiro AT. Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age. Rheumatol Int. 2016 Jan;36(1):117-24.
14 – Lima JE et al. Avaliação do polimorfismo genético pvu II do receptor de lipoproteína de baixa densidade (RLDL) em pacientes com lúpus eritematoso sistêmico. Semina: Ciências Biológicas e da Saúde, Londrina. 2015 Ago; 36(1): 109-22.
15 – Malachias MVB et al. 7a Diretriz Brasileira de Hipertensão Arterial. Arq Bras Cardiol 2016 Set; 107(3).
16 - Kdigo 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, v. 3, jan, 2013. Disponível em: http: // www.kidney-international.org. Acessado em: 12 agosto 2017.
17 - Lotufo P. O escore de risco de Framingham para doenças cardiovasculares. revistadc 18dez.2008; 87(4):232-7.
18 - Kidney International Supplements (2012) 2, 259–274;. Disponível em: http: // www.kidney-international.org. Acessado em: 12 agosto 2017.
19 – Stone NJ et al. 2013 ACC / AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63:2889-934.
Published
2018-11-20
How to Cite
TOCANTINS VIANA LOBATO, Edienny Augusta et al. Evaluation Of Risk Factors In Cardiovascular Patients With Diagnosis Of Systemic Lupus Erythematosus (SLE). International Archives of Medicine, [S.l.], v. 11, nov. 2018. ISSN 1755-7682. Available at: <http://imedicalsociety.org/ojs/index.php/iam/article/view/2866>. Date accessed: 06 dec. 2019. doi: https://doi.org/10.3823/2590.
Section
Rheumatology

Most read articles by the same author(s)